Adoram Therapeutics SA

Adoram Therapeutics is a spin-off from the University of Geneva, discovering next generation small molecule therapies for cancer and inflammation based around GPCR drug targets, the largest class of receptors in the human genome. Adoram specializes in small molecule drugs that have a sought after 'allosteric' mode of action, making them safer and more effective than conventional small molecules. Company founders include Dr. David Pejoski (Co-CEO / COO), Dr. Hesham Hamed (Co-CEO / CSO), and drug discovery advisor Prof. Leonardo Scapozza.